Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

Go back to Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
(NASDAQ: ALLR) Delayed: 1.25 -0.17 (11.97%)
Previous Close $1.42    52 Week High
Open $1.36    52 Week Low
Day High $1.37    P/E N/A 
Day Low $1.25    EPS
Volume 236,972       

(NASDAQ: ALLR) Delayed: 1.25 -0.17 (11.97%)
Previous Close $1.42    52 Week High
Open $1.36    52 Week Low
Day High $1.37    P/E N/A 
Day Low $1.25    EPS
Volume 236,972